Dainippon Sumitomo Pharma Co Ltd

Type: Company

Name: Dainippon Sumitomo Pharma Co Ltd (Dainippon Sumitomo Pharma Co. Ltd)

Nationality: Japan

Web Address: http://www.ds-pharma.co.jp/

Fact Sheet: Fact Sheet for Dainippon Sumitomo Pharma Co Ltd

First reported May 21 2013 - Updated May 22 2013 - 1 reports

Merck & Co Inc

Merck insomnia drug is safer at lower dose, FDA staff says

Merck & Co.'s experimental insomnia drug, designed to turn off wakefulness rather than subdue the brain into slumber like Ambien, may be safe only at doses lower than what the company has proposed, U.S. regulators said.Doses that Merck studied of as much ... [Published North Jersey.com - May 21 2013]

Entities: Merck & Co Inc, Insomnia, FDA Food & Drug Administration

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Court upholds Mylan's patents on COPD drug

Federal appeals court reverses decision in case against SunovionRelated ContentPITTSBURGH — A federal appellate court has ruled in favor of Mylan in a case involving a drug for chronic obstructive pulmonary disease, the drug maker said Tuesday.Mylan said ... [Published Drug Store News - May 21 2013]

Entities: Chronic Obstructive Pulmonary Disease, Patent, Drugs, Brovana

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Ajinomoto Co Inc

Japan Pharma Annual Meeting Snapshot: Eisai, Dainippon, Shionogi, Ajinomoto, Astellas

The annual earnings meetings of Eisai, Dainippon Sumitomo, Shionogi, Ajinomoto and Astellas highlight critical issues impacting Japanese pharma, from the evolving domestic generics market, choosing whether to enter the biosimiliars fray and the impact ... [Published The Rose Sheet - May 21 2013]

Entities: Shionogi, Ajinomoto Co Inc, Eisai Co Ltd, Astellas Pharma Inc

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Shionogi

Bacterial Partnering Terms and Agreements - 2013 Report Features Over 1,000 Links to Online Copies of Actual Bacterial Deals

(M2 PRESSWIRE via COMTEX News Network) -- Research and Markets (http://www.researchandmarkets.com/research/2ng6vc/bacterial) has announced the addition of the "Bacterial Partnering Terms and Agreements" report to their offering. The Bacterial Partnering ... [Published PredictWallStreet - May 10 2013]

Entities: Aspen Pharmacare Holdings Ltd, Shionogi, Menarini Group

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Dainippon Sumitomo Pharma announces BBI608 Phase 1 Clinical Study Data to be presented at the 2013 ASCO Annual Meeting

Company name: Dainippon Sumitomo Pharma Co., Ltd.Representative: Masayo Tada, President (Securities Codes: 4506, 1st Section of TSE and OSE) Contact: Atsuko Higuchi, Director, Corporate Communications（Phone: +81-6-6203-1407）Osaka, Japan, May 9, 2013 - ... [Published Noodls - May 09 2013]

Entities: Dainippon Sumitomo Pharma Co Ltd, Phase I, clinical study, Cancer, Masayo Tada

First reported May 09 2013 - Updated May 09 2013 - 2 reports

Dainippon Sumitomo Pharma Co Ltd

Change of Directors and Audit & Supervisory Board Members

Company name: Dainippon Sumitomo Pharma Co., Ltd.Representative: Masayo Tada, President (Securities Codes: 4506, 1st Section of TSE and OSE) Contact: Atsuko Higuchi, Director, Corporate Communications（Phone: +81-6-6203-1407）Dainippon Sumitomo Pharma Co., ... [Published Noodls - May 09 2013]

Entities: Masayo Tada, Dainippon Sumitomo Pharma Co Ltd, President Securities Corp

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Takeda Pharmaceutical Co Ltd

Ophthalmics Partnering Terms & Agreements

(M2 PRESSWIRE via COMTEX News Network) -- Research and Markets (http://www.researchandmarkets.com/research/343n2l/ophthalmics) has announced the addition of the " " report to their offering. The Opthalmics Partnering Terms and Agreements report provides ... [Published PredictWallStreet - May 08 2013]

Entities: Ophthalmics, Dainippon Sumitomo Pharma Co Ltd, Les Laboratoires SERVIER, Takeda Pharmaceutical Co Ltd

First reported May 08 2013 - Updated May 08 2013 - 1 reports

DAINIPPON SUMITOMO PHARMA CO., LTD.: Ono and Dainippon Sumitomo reach agreement on expanding business relating to Limaprost into China

Dainippon Sumitomo Pharma Co., Ltd. : Ono and Dainippon Sumitomo reach agreement on expanding business relating to Limaprost into ChinaMay 8, 2013ONO PHARMACEUTICAL CO., LTD. DAINIPPON SUMITOMO PHARMA CO., LTD.Corporate Communications Corporate Commu ... [Published 4 Traders - May 08 2013]

Entities: Dainippon Sumitomo Pharma Co Ltd, China, Relativity, Ono Pharmaceutical

First reported Apr 19 2013 - Updated Apr 19 2013 - 2 reports

Eye-tech firm plans to raise $1 billion to pursue stem cell-based treatments

Retina Institute Japan K.K., which employes Nobel Prize-winning stem-cell technology to treat eye diseases, plans to sell a stake in itself to a group of Japanese companies next month, ahead of a possible initial public offering in five years.The company ... [Published Japan Times - Apr 19 2013]

Entities: treatments, Kyoto University, Age-Related Macular Degeneration

First reported Apr 15 2013 - Updated Apr 15 2013 - 2 reports

Dainippon Sumitomo Pharma Submits Marketing Authorization Application in Australia for Atypical Antipsychotic Agent Lurasidone

Dainippon Sumitomo Pharma Co., Ltd.Australia for Atypical Antipsychotic Agent LurasidoneOsaka, Japan, April 15, 2013 - Dainippon Sumitomo Pharma Co., Ltd. (DSP) (Headquarters: Osaka, Japan; President: Masayo Tada) announces that the Australian Therapeutic ... [Published Noodls - Apr 15 2013]

Entities: Lurasidone, DSP Group Inc, Dainippon Sumitomo Pharma Co Ltd

First reported Apr 08 2013 - Updated Apr 09 2013 - 3 reports

Research and Markets: Central Nervous System Partnering Yearbook 2013: Understand M&A deals and agreements Business Wire

DUBLIN--(BUSINESS WIRE)-- Research and Markets has announced the addition of the report to their offering. The Central Nervous System Partnering Yearbook 2013 report series provides comprehensive understanding and unprecedented access to the partnering ... [Published Yahoo! Finance - Apr 09 2013]

Entities: Central Nervous System, Mergers & Acquisitions, Aspen Pharmacare Holdings Ltd, Menarini Group

First reported Feb 28 2013 - Updated Mar 01 2013 - 3 reports

Research and Markets: Animal Health Partnering Yearbook 2013 Provides Comprehensive Understanding and Business Wire

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/rt32p3/animal_health) has announced the addition of the "Animal Health Partnering Yearbook 2013" report to their offering. The Animal Health Partnering Yearbook ... [Published Yahoo! Finance - Feb 28 2013]

Entities: Animal Health, Aspen Pharmacare Holdings Ltd, Dainippon Sumitomo Pharma Co Ltd, Menarini Group

Quotes

...These cells, as the Nature paper notes, are defined "on the basis of their ability to seed tumors in animal hosts, to self renew and to spawn differentiated progeny." CSC's certainly meet these standards; such cells create non-CSC tumor cells, and if left unchecked, can cause a tumor to regrow, even if the bulk of...

Successful Capital Raise, Data For Lead Candidate, And Small Float Are Opportunitites For Stemline [Published Seeking Alpha - 6 hours ago]

"The lowest strength proposed for marketing by the sponsor is 15 mg," it said. "If a dosage strength lower than 15 mg is unavailable, we would need to consider if the drug could be marketed safely at all, if we believe that a substantial proportion of the indicated population needs a lower dose."

Merck insomnia drug is safer at lower dose, FDA staff says [Published North Jersey.com - May 21 2013]

Marks & Spencer - Co. CEO Bolland is 'doing a fantastic job' and co. "s board fully supports his effort to modernize the co." s infrastructure according to chairman Swannell. (Sunday Telegraph)

EUROPEAN EQUITY OPENING HEADLINE INCLUDING : Anglo American said to seek to seek workforce for Br ... [Published Proactiveinvestors United Kingdom RSS feed - May 20 2013]

...value of perampanel in the treatment of partial seizures," noted Professor Bernhard Steinhoff from the Epilepsiezentrum Kork, Kehl-Kork, Germany. $ "Up to 40% of patients with epilepsy are, or become, refractory to treatment, potentially resulting in impaired quality of life and an increased risk of injury or unexpected sudden death. There is a real need for effective new AEDs with novel modes of action that can be given with the most commonly prescribed AEDs. Perampanel is therefore a very welcome new adjunctive therapy."

First-in-class Fycompa® (perampanel) Pooled Pivotal Phase III Data Published in Epilepsia [Published Sys-Con Australia - May 13 2013]

More Content

sort by: Date \| Relevance
Successful Capital Raise, Data For Lead Candida... [Published Seeking Alpha - 6 hours ago]
COGSTATE LIMITED: Company Secretary Appointment [Published 4 Traders - 15 hours ago]
Favorable Verdict for Mylan Zacks [Published Yahoo! Finance - May 22 2013]
Merck Insomnia Drug Is Safe Only in Lower Doses... [Published Bloomberg - May 22 2013]
Japan Pharma Annual Meeting Snapshot: Eisai, Da... [Published The Rose Sheet - May 21 2013]
Court upholds Mylan's patents on COPD drug [Published Drug Store News - May 21 2013]
Japan Pharma Annual Meeting Snapshot: Eisai, Da... [Published BioPortfolio - May 21 2013]
Merck insomnia drug is safer at lower dose, FDA... [Published North Jersey.com - May 21 2013]
Merck Insomnia Drug Is Safer at Lower Dose, FDA... [Published BusinessWeek - May 20 2013]
Sunovion Presents Results from a One-year, Larg... [Published EON - May 20 2013]
Sunovion Presents Results from a One-year, Larg... [Published Business Wire - May 20 2013]
EUROPEAN EQUITY OPENING HEADLINE INCLUDING : An... [Published Proactiveinvestors United Kingdom RSS feed - May 20 2013]
Sunovion to Present Three Posters on Results of... [Published Yahoo! Finance - May 16 2013]
Actor John O’Hurley Hosts New AAN Epilepsy Video [Published Prlog - May 15 2013]
First-in-class Fycompa® (perampanel) Pooled Piv... [Published Sys-Con Australia - May 13 2013]
Bacterial Partnering Terms and Agreements - 201... [Published PredictWallStreet - May 10 2013]
Viral Partnering Terms and Agreements - 2013 Re... [Published Individual.com - May 09 2013]
Dainippon Sumitomo Pharma announces BBI608 Phas... [Published Noodls - May 09 2013]
Change of Directors and Audit & Supervisory Boa... [Published Noodls - May 09 2013]
DAINIPPON SUMITOMO PHARMA CO., LTD.: Change of ... [Published 4 Traders - May 09 2013]
Ophthalmics Partnering Terms & Agreements [Published PredictWallStreet - May 08 2013]
DAINIPPON SUMITOMO PHARMA CO., LTD.: Ono and Da... [Published 4 Traders - May 08 2013]
Intercept Pharmaceuticals Announces Additional ... [Published OrbiMed Advisors - May 06 2013]
Recently Released Market Study: Sumitomo Corpor... [Published SBWire - May 06 2013]
Deals of the Week Looks at Ultra-Orphan Drug Pr... [Published The IN VIVO Blog - May 05 2013]
"Depression - Pipeline Review, H1 2013" now ava... [Published Live-PR.com - May 05 2013]
Now Available: Gram-Positive Bacterial Infectio... [Published Live-PR.com - May 05 2013]
Intercept Pharmaceuticals Announces Additional ... [Published Yahoo! Finance - Apr 30 2013]
Intercept Pharmaceuticals Announces Additional ... [Published Nasdaq - Apr 30 2013]
Intercept Pharmaceuticals Announces Additional ... [Published Zecco - Apr 30 2013]

sort by: Date \| Relevance
Deals of the Week Looks at Ultra-Orphan Drug Pr... [Published The IN VIVO Blog - May 05 2013] In the first half of 2013, two drugs will have launched in the US priced at $250,000 per patient annually: Both address serious, ultra-rare diseases and are backed by KOLs and patients. But the similarities stop there. Three months into its launch, ...
Edison Pharmaceuticals inks deal with Japan's D... [Published PBR - News - Apr 01 2013] Edison Pharmaceuticals has signed a research/development and commercialization agreement with Dainippon Sumitomo Pharma (DSP) for the development of EPI-743 and EPI-589 in Japan. ...
Deals of the Week: An Update On A Potential Pfi... [Published The IN VIVO Blog - Mar 29 2013] br /> Pfizer's Chairman and CEO Ian Read doesn’t make himself available for interviews readily, so a March 26th note from Sanford Bernstein’s esteemed pharma analyst Tim Anderson caught our attention pronto. The note describes a teleconference call ...
Biobuck M&A in Full Gear [Published I Am Biotech - Feb 01 2013] The 2012 M&A results are in and trends are mixed. Last year was a down year in terms of total acquisitions and total dollar value amounts vs 2011. What was not down however was the earnout structures embedded in these deals. More and more M&A transactions ...
The 10 biggest VC-backed acquisitions of 2012 [Published Venturebeat - Dec 28 2012] While 2012 saw some spectacularly large IPOs like Facebook and Workday, it also had its share of major mergers and acquisitions. In the tech sector, the acquisitions of Instagram, Yammer, and Nicira Networks were especially big news. Companies ...